Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6253782 | 1.00 | TDP1 (0.50) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL4235227 | 1.00 | TDP1 (0.50) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL6253901 | 1.00 | TDP1 (0.50) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL6253810 | 1.00 | TDP1 (0.50) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL11050266 | 1.00 | TDP1 (0.50) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL28168552 | 1.00 | TDP1 (0.50) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL1310407 | 1.00 | TDP1 (0.50) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL380758 | 0.97 | — | — | |
| SCHEMBL629320 | 0.89 | — | — | |
| SCHEMBL15871737 | 0.89 | KDM4E (0.55) | CA1CA2CA12CA9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| WO-2025132542-A1 | MACROCYCLIC OREXIN AGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-06-26 | — | — | WO | disclosed |
| EP-4380937-A1 | CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR PROTEINS | Rayzebio, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| EP-4373819-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2024-05-29 | — | — | EP | disclosed |
| EP-4359006-A1 | ANTISENSE COMPOUNDS AND METHODS FOR TARGETING CUG REPEATS | Entrada Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-4337264-A1 | COMPOSITIONS AND METHODS FOR MODULATING TISSUE DISTRIBUTION OF INTRACELLULAR THERAPEUTICS | Entrada Therapeutics, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-4337261-A2 | COMPOSITIONS AND METHODS FOR MODULATING MRNA SPLICING | Entrada Therapeutics, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-4337263-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERFERON REGULATORY FACTOR-5 (IRF-5) ACTIVITY | Entrada Therapeutics, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| WO-2024052692-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024052702-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-03-14 | — | — | WO | disclosed |
| US-5130312-A | Gastrointestinal motility stimulators | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-07-14 | — | — | US | disclosed |
| EP-0268148-B1 | TETRAHYDRONAPHTHALENE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | F. HOFFMANN-LA ROCHE AG (CH) | 1991-12-11 | — | — | EP | disclosed |
| US-5041454-A | Stimulate gastrointestinal motility | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-08-20 | — | — | US | disclosed |
| US-4975439-A | Gastrointestinal motility stimulating properties | JANSSEN PHARMACEUTICAL N.V. (BE) | 1990-12-04 | — | — | US | disclosed |
| US-4906643-A | Substituted N-(3-hydroxy-4-piperidinyl)benzamides as gastrointestinal agents | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-03-06 | — | — | US | disclosed |
| EP-0318196-A2 | Colloidal metals in monomers or polymers | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1989-05-31 | — | — | EP | disclosed |
| EP-0309043-A2 | Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-03-29 | — | — | EP | disclosed |
| US-4808605-A | Tetrahydronaphthalene derivatives as calcium antagonists | HOFFMANN-LA ROCHE INC. (US) | 1989-02-28 | — | — | US | disclosed |
| EP-0299566-A2 | Novel substituted N-(3-hydroxy-4-piperidinyl)benzamides | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-01-18 | — | — | EP | disclosed |
| EP-0268148-A1 | Tetrahydronaphthalene derivatives and medicaments containing them | F. HOFFMANN-LA ROCHE AG (CH) | 1988-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TDP1 236/4885CA1 4622/4885CA2 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.